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Neurological disease
Axon degenerationRecessively-inherited deﬁciency in the catalytic activity of calcium-independent phospholipase A2-beta
(iPLA2β) and neuropathy target esterase (NTE) causes infantile neuroaxonal dystrophy and hereditary spas-
tic paraplegia, respectively. Thus, these two related phospholipases have non-redundant functions that are
essential for structural integrity of synapses and axons. Both enzymes are expressed in essentially all neurons
and also have independent roles in glia. iPLA2β liberates sn-2 fatty acid and lysophospholipids from diacyl-
phospholipids. Ca2+-calmodulin tonically-inhibits iPLA2β, but this can be alleviated by oleoyl-CoA. Together
with fatty acyl-CoA-mediated conversion of lysophospholipid to diacyl-phospholipid this may regulate sn-2
fatty acyl composition of phospholipids. In the nervous system, iPLA2β is especially important for the turn-
over of polyunsaturated fatty acid-associated phospholipid at synapses. More information is required on
the interplay between iPLA2β and iPLA2‐gamma in deacylation of neuronal mitochondrial phospholipids.
NTE reduces levels of phosphatidylcholine (PtdCho) by degrading it to glycerophosphocholine and two
free fatty acids. The substrate for NTE may be nascent PtdCho complexed with a phospholipid-binding pro-
tein. Protein kinase A-mediated phosphorylation enhances PtdCho synthesis and may allow PtdCho accumu-
lation by coordinate inhibition of NTE activity. NTE operates primarily at the endoplasmic reticulum in
neuronal soma but is also present in axons. NTE-mediated PtdCho homeostasis facilitates membrane trafﬁck-
ing and this appears most critical for the integrity of axon terminals in the spinal cord and hippocampus. For
maintenance of peripheral nerve axons, iPLA2β activity may be able to compensate for NTE-deﬁciency but
not vice-versa. Whether agonists acting at neuronal receptors modulate the activity of either enzyme remains
to be determined. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism.© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
This review focuses on the intracellular deacylation of phospholipids
in neurons by two related phospholipases of the patatin family:
calcium-independent phospholipase A2-beta (iPLA2β; PNPLA9; Group
VIA PLA2) and neuropathy target esterase (NTE; PNPLA6). While both
these enzymes are expressed in a variety of tissues and cell types, atten-
tion has been attracted to their neuronal functions becausemutations in
their genes give rise to human neurological diseases. General features of
iPLA2β and NTE together with those of other deacylating phospholi-
pases have been the subject of an extensive recent review [1].2. Neural and neuronal phospholipid composition
Phosphatidylcholine (PtdCho) is the major glycerophospholipid
(GPL) in the brain where it is synthesized by the CDP-choline pathway.
The rate-limiting step in this pathway is catalyzed by two isoforms of
CTP:phosphocholine cytidylyltransferase: CTα and CTβ2, of which thespholipids and Phospholipid
nse.latter is the dominant form in brain [2]. In brain, as in other tissues, turn-
over of PtdCho by deacylation may be required to modify PtdCho fatty
acid composition for spatial and temporal variations of membrane ﬂu-
idity; to respond either to varying availability of certain fatty acids via
the diet or to membrane lipid peroxidation; to liberate particular fatty
acids or lysophospholipids with signaling functions; and to restrict
total PtdCho levels within a physiologically-optimal range.
Mice deﬁcient in iPLA2β or NTE have been described and will facil-
itate examination of the roles of these enzymes in maintaining neuro-
nal phospholipid composition. In such investigations it would be
useful to have basic information of mouse neuronal phospholipid
composition under normal conditions: however, this is not readily
available, due primarily to the complexity of neurons and their phys-
iological environment. For example, an adult mouse brain contains
~70 million neurons and ~40 million non-neuronal or glial cells: as-
trocytes, oligodendrocytes and microglia [3]. Moreover, ~10% of the
dry weight of mouse brain is composed of myelin, the lipid-rich, ex-
tended plasma membrane of oligodendrocytes that insulates the
axons of some neurons [4].
Neurons are highly polarized cells that receive chemical signals
from other neurons via synapses on their cell soma or on dendritic
processes; this information is converted into an electrical action po-
tential that is conveyed via an axon, and causes release of another
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neuron or, in some instances, with muscle. Different neurons have
differing functions and highly variable morphologies. For example,
pyramidal neurons in the hippocampus and Purkinje neurons in
the cerebellum have enormous dendritic trees, while inter-neurons
in various neural locations have relatively short dendrites and
axons. Some primary motor neurons in the cerebral cortex project
long axons which terminate in the lumbar spinal cord on secondary
motor neurons; long axons from some of the latter neurons terminate
on muscles in the feet. Pseudo-unipolar sensory neurons with cell
bodies in ganglia just outside the spinal cord have two long axonal
branches: one that receives sensory information from the periphery
(and is, in this manner, equivalent to the dendrites of other neurons);
the other axon conveys information to neurons in the brain. In
humans, each axon of a dorsal root ganglion sensory neuron can be
up to one meter long and maintenance of these huge structures
places a heavy metabolic burden on the cell. Moreover, the two
axons of the sensory neuron have different local environments: the
central axon is myelinated and supported by oligodendrocytes and
astrocytes while, for the peripheral axon, both these functions are ful-
ﬁlled by Schwann cells [5].
Given this heterogeneity, techniques capable of high spatial resolu-
tion are being employed increasingly to deﬁne phospholipid composi-
tion and turnover in neural tissue. MALDI-imaging mass spectrometry
(IMS) has been used to visualize the distribution of different polyunsat-
urated fatty acid (PUFA)-esteriﬁed PtdCho in sagittal sections of the
mouse brain: by this means it has been shown that arachidonic acid
(AA)-containing PtdCho and docosahexaenoic acid (DHA)-containing
PtdCho are enriched in cell layers of the hippocampus and in cerebellar
Purkinje cells, respectively [6].
Notwithstanding the potential of newer techniques such as IMS,
much of the information on the phospholipid composition and turn-
over of neural tissue has been obtained from assays on whole brain
homogenates or sub-cellular fractions enriched in membrane frag-
ments derived frommyelin or synaptic plasmamembranes: represen-
tative data are shown in Table 1. Another approach has been to culture
neurons from neonatal or embryonic rodent tissue under conditions
that greatly reduce the number of surviving glial cells before phospho-
lipid analysis. PtdCho is the major GPL in cultured rat cerebellar gran-
ule neurons [7] as well as murine whole brain [8] (Table 1). However,
while GPL-esteriﬁed PUFA are present at substantial levels in the
whole brain [8], they are barely detectable in the neuronal cultures
[7] (Table 1): this is because neurons lack the required desaturases
and rely instead on supply of PUFA from glial cells, particularly astro-
cytes [9]. It is apparent also that PUFA are esteriﬁed with phosphati-
dylethanolamine (PtdEtn) more than with PtdCho [8] and that, in
myelin, PtdEtn is the dominant GPL [4] (Table 1).
The observation that synaptic plasma membrane preparations are
highly enriched in PUFA-esteriﬁed GPL [10] (Table 1) hints at the het-
erogeneity in GPL composition that exists within different domains of
neurons themselves: this may arise by several possible mechanisms,
two of which have been studied using cultures of sensory neurons
from rodent superior cervical ganglia (SCG). These neurons can be cul-
tured under conditions that allow independent compartmentalizedTable 1
Rodent brain tissue preparations: glycerophospholipid (GPL) composition.
Preparation PtCho/PtdEtn/
(PtdSer+PtdIns)
GPL, PUFA (mol%) Ref.
Whole brain 0.45/0.37/0.18 PtdCho, 7; PtdEtn, 28 [8]
Myelin 0.35/0.49/0.16 All GPL, 59 [4]
Synaptic PM 0.51/0.32/0.17 PtdCho, 48; PtdEtn, 93 [10]
Cultured neurons 0.56/0.34/0.10 All GPL, b5 [7]
PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdSer, phosphatidyl-
serine; PtdIns, phosphatidylinositol; PUFA, poly-unsaturated fatty acid; PM, plasma
membranes.analysis of the ability of soma and axons to incorporate [3H]choline
into PtdCho. It has been shown that PtdCho is synthesized in both
these compartments [11]. Moreover, while CTα is expressed only in
the soma, CTβ2 is also expressed in the distal axon. In CTβ2-null
mice [3H]PtdCho synthesis is no longer detected in the distal axon
compartment and neurons cultured from these mice show reduced
amounts of axonal branching suggesting that locally-synthesized
PtdCho may be important for axonal bifurcation [12].
In a different approach, IMS has been used to characterize the
PUFA composition of PtdCho in SCG explant cultures that contain
glial cells as well as neurons. While only very low levels of PUFA-
esteriﬁed PtdCho were present in the ganglia (i.e., in neuronal
soma), levels several-fold higher were found in the axons and in-
creased in a proximal to distal fashion. Evidence was presented that
this gradient of PUFA-esteriﬁed PtdCho was maintained by energy-
and actin-dependent transport [13]. Thus, local PtdCho synthesis
and speciﬁc transport mechanisms may contribute to GPL heteroge-
neity within different regions of neurons.
The foregoing demonstrate that useful preliminary data on brain
phospholipid composition and some aspects of its turnover have
been obtained from experiments involving measurement of various
GPL species in homogenates or subcellular fractions from whole
brain or cultured neurons, in the presence or absence of radiolabelled
precursors such as choline or PUFA. Such methods have been used to
examine the biochemical consequences of inactivating iPLA2β or
NTE and these will be described later in this review. However, to dis-
cern phospholipid turnover in the major compartments (soma, axon,
dendrites) of neurons under physiologically-realistic conditions –
with local provision of PUFA from glia – presents substantial technical
challenges for the future.
3. Neural phospholipid deacylation: iPLA2β and NTE
To consider the contributions of iPLA2β and NTE to GPL deacylation
in the brain, the remainder of this review describes their biochemistry
and their distribution in, and consequences of their deletion from, the
nervous system (Table 2).
3.1. Biochemistry of iPLA2β and NTE
3.1.1. The domain architectures of iPLA2β and NTE
A region of ~160 amino acids within the catalytic (patatin-like) do-
mains of the two enzymes has 28% sequence identity, including key
serine and aspartate residues, and a putative nucleotide binding
motif, GXGXXG (Fig. 1; for alignment see [14]). The N-terminal do-
main of iPLA2β is dominated by 8 ankyrin repeats that may allow
tetramerization of the enzyme [15]. Two catalytically-active isoforms
of iPLA2β result from alternative splicing such that the larger form
(type 2), but not the smaller (type 1) has a 54-amino acid insertion
in its eighth ankyrin repeat. Type 2- but not type 1-iPLA2β is activated
by ATP [16] and associates with particulate rather than soluble subcel-
lular fractions [17]. A region of ~140 residues near the C-terminus of
iPLA2β has multiple contact points for binding Ca2+-calmodulin [18]
(Fig. 1).
At its N-terminus NTE has a single transmembrane segment that
serves to tether the protein to the cytoplasmic face of the endoplasmic
reticulum (ER) (Fig. 1; [19]). Two regions within the N-terminal puta-
tive regulatory domain of NTE (183–318 and 494–745) have modest
(~10% and ~16%) identity to the cAMP-binding regulatory subunit of
protein kinase A (PKA) (Fig. 1): to date, no evidence has been reported
that these regions functionally bind cAMP (see below). A short region
(130–158) closer to the N-terminus of human NTE has homology to
the motif on the PKA regulatory subunit that mediates binding to the
catalytic subunit (Fig. 1). Recombinant polypeptides containing
the equivalent region in Swiss cheese protein (SWS), the Drosophila
NTE orthologue, bind to the catalytic subunit of PKA-C3 but not
Table 2
iPLA2β and NTE: biochemistry, neural distribution and neural KO phenotype.
Category iPLA2β NTE
Biochemistry
GPL bond cleaved sn-2 (PLA2) sn-2 then sn-1 (PLB)
Inhibitors BEL +++, (S)>(R) BEL +++, (S) vs (R)?
MAFP +++ MAFP +++
FA-TFMK (P>AA) FA-TFMK (AA>P)
Neuropathic OP ? Neuropathic OP +++
Distribution
Neural tissue Neurons +++ Neurons +++
Astrocytes + Astrocytes +
Subcellular Cytoplasm +++ ER (cytoplasmic face) +++
Nucleus ++
Synapses ++ Axons +
Neural KO phenotype
Brain GPL Decreased lysoPtdCho Increased PtdCho
Decreased PUFA-GPL turnover
Neuropathology Extensive in CNS and PNS Spinal cord and hippocampus
Synapses and axons Axons
Mitochondria
GPL, glycerophospholipid; BEL, bromoenol lactone ((R) and (S) enantiomers); MAFP,
methylarachidonylﬂuorophosphonate; FA-TFMK, fatty acyl-triﬂuoromethylketone; P,
palmitoyl; AA, arachidonoyl; OP, organophosphorus compound; PUFA, poly-unsaturated
fatty acid; CNS and PNS, central and peripheral nervous systems. For references see text.
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protein (AKAP) for PKA-C3, localizing the kinase to the endoplasmic
reticulum and inhibiting its catalytic activity [20]. The expression of
mammalian homologues of PKA-C3 in brain suggests that NTE may
play an analogous regulatory role as an AKAP although it is not
known whether this would affect phospholipid turnover.3.1.2. Substrates and inhibitors of iPLA2β and NTE
Substrate speciﬁcities have been examined by incubating puriﬁed
recombinant forms of the enzymes with mixed phospholipid-
detergent micelles. It has been noted that rates and selectivities ob-
served in such assays are profoundly affected by the physicochemical
nature of the substrate [21]. Notwithstanding this important caveat,
iPLA2β was found to be equally effective with equivalent PtdCho
and PtdEtn substrates and to hydrolyze the sn-2 acyl bond of
dipalmitoyl-PtdCho at 5-times the rate for the sn-1 bond [22]. Simi-
larly, antisense oligonucleotide-mediated reduction of iPLA2β levels
in a macrophage-like cell line inhibited conversion of [3H]PtdCho to
[3H]lyso-PtdCho conﬁrming that the essential action of iPLA2β is to
hydrolyze the sn-2 bond of phospholipid to generate lysophospho-
lipid and free fatty acid [23].
When a puriﬁed recombinant polypeptide containing the catalytic
domain of NTEwas incubatedwithmixed phospholipid-detergentmi-
celles, fatty acidwas liberated fromdioleoyl-PtdCho at about twice the
rate as from dioleoyl-PtdEtn. More importantly, it was shown that
both acyl bonds of diacyl-PtdCho were cleaved sequentially with the
sn-2 (rate-limiting) followed by the sn-1 (rapid) and so NTE degrades
PtdCho to glycerophosphocholine (GroPCho) plus two free fatty acids
[14]. Thus, NTE has phospholipase-B activity and this was conﬁrmedFig. 1. Domain architecture of iPLA2β and NTE. Polypeptide chains are shown as thin black li
calcium-calmodulin-binding domain; TM, transmembrane domain; ID, interaction doma
domains; CAT, catalytic domain, showing critical DSD (aspartate, serine, aspartate) residu
shown in this ﬁgure.by the demonstration that conversion of [14C]PtdCho to [14C]GroPCho
in mammalian cell lines was enhanced by over-expression of NTE and
inhibited by siRNA-mediated reduction of NTE levels [24].
Given the homology between catalytic domains of iPLA2β and NTE
[14], it is not surprising that both enzymes are susceptible to inhibition
by low concentrations of bromoenol lactone (BEL), methylarachidonyl-
ﬂuorophosphonate and fatty acyl-triﬂuoromethylketones (TFMK); al-
though, while palmitoyl-TMFK is more potent than arachidonoyl-
TFMK as an inhibitor of iPLA2β, the rank potencies are reversed for
NTE [14] (Table 2). A corollary of this observation is that the effects of
these compounds on cultured cells, tissues or whole animals cannot
be readily attributed to inhibition of one or other enzyme. In the case
of BEL, racemic mixtures of this chiral compound have been resolved
into (S)- and (R)-enantiomers and the former has been shown to be
10-fold more potent than the latter as an inhibitor of iPLA2β: by
contrast, (R)-BEL is 10-fold more potent than (S)-BEL as an inhibitor
of another patatin-family phospholipase, calcium-independent phos-
pholipase A2-gamma (iPLA2γ; PNPLA8). This enantioselective discrim-
ination has allowed identiﬁcation of iPLA2β, rather than iPLA2γ, as the
mediator of hormone-induced arachidonate release from smooth mus-
cle cells [25].Whether NTE is inhibited selectively by one or other of the
BEL enantiomers remains to be determined.
Historically, the most important covalent inhibitors of NTE are the
neuropathic organophosphorus (OP) compounds that cause distal ax-
onal degeneration of both central and peripheral nervous systems in
humans and experimental animals. Interest in the delayed-onset par-
alyzing syndrome induced by these OPs led to the discovery of NTE
[26]. This aspect of NTE biochemistry has been reviewed previously
[27,28]. However, two OP inhibitors of NTEmerit mention here. Cresyl
saligenin phosphate, the active metabolite of tri-ortho-cresyl phos-
phate [29], was responsible for thousands of cases of OP-induced
delayed neuropathy during the 20th century [30]. Ethyloctylphos-
phonoﬂuoridate was speciﬁcally developed as an extraordinarily
potent NTE inhibitor determined by in vitro assay with an artiﬁcial
ester substrate [31]; surprisingly, in mice, this compound did not
induce delayed-onset axonal degeneration, but a sub-acute, fatal
brain edema [32,33]. However, subsequent experiments with NTE-
deﬁcient mice indicated that the target for this toxicity was not neu-
ral NTE but a different serine hydrolase [34]. The latter ﬁnding high-
lights the caution required in interpreting in vivo effects of a
compound based on its in vitro potency. In this regard, the efﬁcacy of
neuropathic OPs as inhibitors of iPLA2β has not been assessed and so
some toxic effects attributed to inhibition of NTE might be mediated
via iPLA2β. Interestingly, peripheral nerves are not damaged in genet-
ic NTE-deﬁciency in humans and mice but do degenerate in genetic
iPLA2β-deﬁciency (see below). Thus, peripheral nerve axon degener-
ation in OP-induced neuropathy may result from inhibition of iPLA2β
activity.3.1.3. Physiological regulation of iPLA2β and NTE activities
Earlier proposals that themain function of iPLA2β is to allow contin-
uous deacylation/reacylation at the sn-2 position of phospholipids [35]
or simply to degrade excess phospholipid [36] have been challenged by
the notion that it is more important in speciﬁc signaling pathways [37].nes with domains represented as rectangles. ANK 1–8, ankyrin repeat motifs 1–8; CaM,
in (putative PKA-C3 homologue-binding); CNB, cyclic nucleotide binding-homology
es. The shorter (type-1) isoform of iPLA2β that lacks the 54-amino acid insertion is
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marily to affect phospholipid turnover, or as a generator of signaling
molecules, depends on the cellular and subcellular context (see below).
The majority of iPLA2β activity in some cell types is thought to
exist as tonically-inhibited ternary complexes of Ca2+-calmodulin-
iPLA2β [17]. Elegant experiments with the puriﬁed recombinant en-
zyme have revealed that one mechanism whereby iPLA2β is released
from this inhibition is a self-catalyzed reaction in which a fatty acyl
group is transferred from acyl-CoA to covalently attach to a nucleo-
philic amino acid within the protein: among the fatty acyl-coAs only
oleoyl-coA appears to be able to alleviate the Ca2+-calmodulin-
mediated inhibition [38]. This is proposed to initiate a cascade
whereby nascent oleic acid liberated from membrane phospholipid
by the action of iPLA2β becomes available for esteriﬁcation with
CoA-SH so that the resulting oleoyl-CoA can propagate the disinhibi-
tion of further complexes of Ca2+-calmodulin-iPLA2β. Importantly,
iPLA2β can catalyze acyl cycling in the presence of oleoyl-coA; the lat-
ter is thus an initiator, and fuel for maintenance, of local iPLA2β activ-
ity [38]. It is interesting to compare this novel regulatory mechanism
with the well-known ability of acyl-coAs to react with the free sn-2
moiety of lysophospholipids to regenerate diacyl-GPLs [35]. Oleoyl-
GPLs comprise ~22–24% of the total PtdCho and PtdEtn in mouse
brain [8] and the extent to which oleoyl-CoA mediated activation
contributes to the regulation of iPLA2β in neurons warrants further
investigation.
In addition to this disinhibition mechanism, correct intracellular
localization of iPLA2β is essential to allow access to its phospholipid
substrates. Studies in non-neuronal cells indicate that certain intra-
cellular signaling pathways can induce type 1-iPLA2β to translocate
from the cytoplasm to associate with membranes. Thus, in pancre-
atic beta-cells glucose and elevated cAMP induce iPLA2β translo-
cation to the peri-nuclear region [39], while in myeloid cells
activation of FcγRI causes protein kinase C-mediated translocation
of iPLA2β to the plasma membrane [40]. On the other hand, in
P388D1 macrophage-like cells iPLA2β does not appear to translocate
in response to stimuli [41]. These analyses are complicated by the
propensity of iPLA2β to undergo proteolysis and of the resulting
large fragments to associate with different cellular compartments
[42]. It is unknown whether this proteolysis is physiologically sig-
niﬁcant. The reasons for the apparently differing modes of regulation
of iPLA2β in different cell types and whether translocation of type
1-iPLA2β is inducible in neurons remain to be resolved.
NTE is permanently attached to the cytoplasmic face of the ER,
so particular mechanisms must operate to regulate its activity. The
most deﬁnitive information in this regard is from experiments on
Saccharomyces cerevisiae where activity of the NTE orthologue,
nte1p, has been shown to require the presence of the cytoplasmic
phospholipid-binding protein, sec14p [43]. A sec14p–PtdCho complex
was previously reported to inhibit the activity of the yeast CTP:
phosphocholine cytidylyltransferase orthologue and thereby regulate
PtdCho synthesis [44]. In addition, sec14p is required for maintaining
levels of Golgi membrane diacylglycerol (DAG) that, in turn, are criti-
cal for vesicular transport to the plasma membrane [45]. Thus, in
yeast, the CDP-choline pathway for PtdCho synthesis is closely linked
to the functioning of the constitutive secretory pathway; moreover,
evidence has been presented that excess PtdCho is intrinsically toxic
to the yeast secretory pathway [46].
In mammalian cells, the ﬁnal step of the PtdCho synthetic pathway
ismediated by choline phosphotransferase (CPT1) that localizes to the
Golgi membrane [47]. Thus, one route for metabolic depletion of Golgi
DAG is via condensation with CDP-choline to form PtdCho. Nascent
PtdChomust be transferred from the Golgi to other intracellularmem-
branes, notably the ER. In mammalian cells this transport is mediated
by Nir2, a peripheral Golgi protein with a phospholipid-binding do-
main, that is proposed to transfer phosphatidylinositol from ER to
Golgi and PtdCho from Golgi to ER [48,49]. Thus, Nir2 may functionas a mammalian homologue of sec14p and a Nir2–PtdCho complex
not only might negatively-regulate activity of CTP:phosphocholine
cytidylyltransferase, but also provide the physiological substrate for
NTE.
The function of the rather degenerate cyclic nucleotide binding-
homology (CNB) domains of NTE (Fig. 1) has been investigated. Pub-
lished [50] and unpublished (Y. Li and P. Glynn) studies have not
found evidence that cAMP directly binds NTE or directly modulates
its catalytic activity. Thus, these CNB domains probably have a
protein-binding rather than a cAMP-binding function. Given the con-
servation of the domain structure of NTE orthologues in all eukaryotic
cells [24] the function of these CNB domains should be similar in yeast
and human. In yeast mutants devoid of cAMP-phosphodiesterase
activity, exogenous cAMP inhibits GroPCho production, but does not
in mutants that also lack bcy1p, the regulatory subunit of PKA (Y. Li
and P. Glynn, unpublished). These observations suggest that NTE is
inhibited, directly or indirectly, by PKA-mediated phosphorylation.
This effect would augment, in a coordinated manner, the increased
mass of cellular PtdCho that is effected by enhancement of PtdCho
synthesis by PKA-mediated phosphorylation of choline kinase [51,52].3.2. Neural and subcellular distribution of iPLA2β and NTE
Deﬁnitive data in this area are limited by the quality of antibodies
available for detection of the endogenous proteins by immunohisto-
chemistry (IHC) in mouse brain. Shinzawa and colleagues [53]
commented on this lack of antibodies to iPLA2β and instead analyzed
mouse brain sections by in situ hybridization (ISH) to show that
iPLA2βmRNA is expressed in neurons of the cerebral cortex, cerebel-
lum, spinal cord and dorsal root ganglia. By contrast, iPLA2β mRNA
appeared absent from oligodendrocytes of the corpus callosum and
Schwann cells of the peripheral nerve [53]. The most detailed IHC
iPLA2β localization study to date used a goat anti-peptide antibody
on sections of monkey brain [54]. By this means, strong iPLA2β-
immunoreactivity was detected in neurons in the cerebral neocor-
tex, hippocampus, amygdala, caudate nucleus, putamen, nucleus
accumbens, and midbrain and brainstem nuclei while weaker immu-
noreactivity was observed in the thalamus, hypothalamus and globus
pallidus. Neuronal soma of cerebellar Purkinje and granule neurons
were only weakly immunoreactive while the molecular layer was
densely stained. By IHC at both light- and electron-microscopy levels,
iPLA2β appeared absent from glia and cerebral vasculature [54].
The most detailed description of the neural distribution of NTE
was by IHC on frozen sections of adult chicken brain using a polyclon-
al anti-peptide antibody: NTE was present in neurons in the cerebral
cortex, cerebellum, optic tectum, spinal cord and dorsal root ganglia
but was not detected in glia [55]. NTE is expressed in chicken (and
human) brain at levels 3–4-times greater than in mouse brain [56].
The relatively low level of expression of NTE in mouse brain and a
high degree of amino acid sequence identity between NTE in different
mammalian species (rendering mammalian NTE peptides poorly im-
munogenic) have hindered IHC for NTE distribution in mouse brain.
However, ISH indicates that, in adult mouse brain, NTE mRNA is
found in essentially all neurons and is particularly evident in large
neurons [57].
By IHC on chicken brain sections NTE was evident predominantly
in neuronal soma, but in large neurons, such as those in cerebellar nu-
clei, was also detected in proximal axons. Moreover, 8–9 h after ap-
plication of a ligature to the chicken sciatic nerve, immunoreactive
NTE was observed to accumulate both proximally and distally to the
nerve block, indicating that NTE undergoes fast axonal transport
[55]. Ong and colleagues did not report detection of iPLA2β in mon-
key axons, but by electron microscopy found immunoreactive materi-
al on synaptic vesicles in axon terminals or on the post-synaptic
density in dendritic spines. Interestingly, iPLA2β reactivity was not
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ments of individual synapses [54].
Thus, by the relatively limited number of published IHC studies,
both NTE and iPLA2β appear to be present in neuronal soma, axons
and some synaptic terminals, but absent from glia. However, while
expression levels in glia are relatively low, functional assays on cul-
tured astrocytes from neonatal rodent brain suggest that these pro-
teins are indeed present and play important roles in these cells. In
cultured rat cerebellar astrocytes, depletion of intracellular Ca2+
stores induced opening of plasma membrane Ca2+ channels; this
store-operated calcium entry (SOCE) appeared to be mediated by
lysophospholipid generated by the action of iPLA2β, because SOCE
could be inhibited by chemical inhibition of this enzyme or by
anti-sense oligonucleotide-mediated knock-down [58]. In cultured
mouse cerebrocortical astrocytes, incorporation of [14C]choline into
[14C]GroPCho (via [14C]PtdCho) was inhibited by OP compounds
known to inhibit NTE activity [59]. More signiﬁcantly, genetic rescue
experiments in NTE-deﬁcient Drosophila identiﬁed phenotypes which
might be attributable to independent effects on neurons and glia (see
below).
Biochemical fractionation experiments showed that iPLA2β and
NTE are associated predominantly with soluble and membrane frac-
tions of brain homogenates, respectively [60,61]. Studies in which
GFP-tagged NTE constructs were expressed in monkey kidney COS
cells localized NTE to the cytoplasmic face of the ER [18]. Likewise,
in cultured mouse hippocampal neurons, immunoreactive endoge-
nous NTE co-localizes with calnexin, an ER marker [62]. In rat brain
homogenates, ~15% of iPLA2β activity is associated with the particu-
late fraction [60]. By expressing type 2-iPLA2β in COS cells and frac-
tionation of cell homogenates, Larsson Forsell and colleagues [16]
concluded that this larger isoform is predominantly associated with
membrane fractions. By contrast, when type 1- and type 2-iPLA2β
were individually expressed in Sf9 insect cells (with relatively much
less endogenous iPLA2 activity) both isoforms were found in compa-
rable amounts in soluble and particulate fractions [15]. By western
blotting of fractions from homogenates of mixed neuronal–glial cul-
tures from neonatal rat cerebral cortex or hippocampus it was
shown that the majority of immunoreactive iPLA2β with an apparent
MW ~85 kDa was soluble but that a minority, with apparent MW
~88 kDa, was associated with a nuclear fraction [54]. Moreover, by
electron microscopy on monkey brain sections, immunoreactive
iPLA2β was detected on the nuclear envelope of neurons and some-
times within the nucleoplasm, whereas, by contrast, the neuronal so-
matic cytoplasm was only lightly labeled [54].
In summary, both iPLA2β and NTE appear to be expressed to vary-
ing degrees in most neurons and probably also, at lower levels, in as-
trocytes. In neurons, iPLA2β is present in both the soma and at
synaptic terminals, while NTE is primarily detected in the soma but
can also be shown to undergo fast axonal transport. At a subcellular
level, NTE is anchored to the ER while iPLA2β, in one or other of its
two isoforms, may be associated with the cytoplasm, nucleoplasm,
nuclear envelope and membranes associated with synaptic terminals
(Table 2).
3.3. Contributions of iPLA2β and NTE to phospholipid deacylation in the
brain
Mice with constitutive deletion of iPLA2β (iPLA2β-KO) have re-
duced male fertility and defective sperm motility [63] and their pan-
creatic beta-cells show impaired insulin secretion in response to
glucose and forskolin challenge [64]. At 4–5 months of age, when
these iPLA2β-KO mice show no obvious neurological signs, analysis
of whole brain GPL revealed changes that reﬂect deﬁciency in turn-
over of sn-2-esterﬁed PUFA [65]. Thus, lysoPtdCho was reduced by
~40% (~10% total GPL in wild-type, ~6% in iPLA2β-KO), while PtdEtn
increased by ~20% (30% total GPL in wild-type, 36% in iPLA2β-KO).The most marked change in fatty acid esteriﬁed with GPL was re-
duced PUFA associated with PtdEtn (AA reduced by ~6%, DHA re-
duced by ~10%); this coincided with reduced (~16%) incorporation
into brain PtdEtn of intra-arterially infused [14C]-DHA [65].
Constitutive deletion of NTE in mice causes embryonic lethality
due to impaired formation of both the placenta and vasculature
[66]. The biochemical consequences of deleting NTE selectively in
mouse neural tissue have been analyzed in nestin-cre:NTEﬂ/ﬂ condi-
tional knock-out mice (NTE-cKO). In these mice, whole brain PtdCho
levels are increased by 15–20%, much the same as the increase
detected within 1–2 days of dosing wild-type mice with an OP inhib-
itor of NTE [67]. These changes are consistent with a role for NTE in
maintaining PtdCho homeostasis. Moreover, two further details are
signiﬁcant: ﬁrst, brain PtdCho levels return to normal levels a few
days after the last dose of OP inhibitor, indicating that this pool of
PtdCho is quite dynamic; second, the same level of increase (15–
20%) in brain PtdCho levels is detected in wild-type mice shortly
after OP-dosing and in undosed NTE-cKO mice at both 1–3 months
old and 6–12 months old, indicating that PtdCho does not accumulate
progressively, but instead rapidly attains a new steady-state level that
is maintained thereafter [67]. The magnitude of brain PtdCho increase
in NTE-cKO mice is similar to that found in NTE-deﬁcient Drosophila
Swiss cheese mutants, attesting to the importance of PtdCho homeo-
stasis in all eukaryotic cells [68].
Thus, biochemical measurements on whole brain homogenates
from gene-knock-out mice indicate that NTE activity reduces PtdCho
levels while iPLA2β is primarily involved in the turnover of PUFA at
the sn-2 position of phospholipids (Table 2).
3.4. Neurological effects of iPLA2β- and NTE-deﬁciency
Over 40 uniquemutations in the PLA2G6 gene that encodes human
iPLA2β are associated with a neurological condition, infantile neuro-
axonal dystrophy (INAD) and neurodegeneration with brain iron ac-
cumulation (NBIA) [69]. These disorders result from degeneration in
the central and peripheral nervous systems causing progressive im-
pairments in sensory, motor and cognitive functions with onset
before 2 years of age and death before 10 years old. Deﬁning patho-
logical features include cerebellar atrophy and iron accumulation in
the globus pallidus [70]. By contrast, different mutations in PLA2G6
are associated with dystonia-parkinsonism that has a much later
onset (15–30 years) and does not feature iron accumulation or cer-
ebellar atrophy [71]. Puriﬁed recombinant forms of iPLA2β with
point mutations associated with either INAD/NBIA (6 mutations) or
dystonia-parkinsonism (3 mutations) were assessed and only the for-
mer constructs showed impaired catalytic activity relative to the
wild-type enzyme [72]. Thus, although dystonia-parkinsonism is
inherited recessively and reﬂects a loss of function in PLA2β, this pre-
sumably reﬂects a protein-binding property rather than its ability to
hydrolyze phospholipid.
The pathological hallmark of INAD is the presence of large spher-
oids of accumulated material in distal axons and synaptic terminals
of both central and peripheral nervous systems. These spheroids are
also evident in mice with constitutive deletion of iPLA2β [53,73]. Clin-
ical signs in these mice, detected by grip strength, rotarod perfor-
mance and other sensorimotor tests, appear relatively late in life
(>1 year old) compared to the onset in human INAD. Interestingly,
neuropathological changes in the iPLA2β-null mice are ﬁrst detected
(by ~4 months) in the cerebellum [53,73] and, by 13–18 months, cer-
ebellar atrophy, as seen in human INAD, is obvious [74]. Spheroid for-
mation is observed throughout the nervous system, but is particularly
prominent in brain stem nuclei and the spinal cord. In addition, by
2 years of age, substantial numbers of axons are lost from peripheral
nerves [53]. Long before clinical signs, at 15 weeks of age, ultra-
structural examination reveals abnormal and degenerating mitochon-
dria in the perinuclear space of large neurons and in large myelinated
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expanded and loose pre-synaptic membranes containing synaptic
vesicles are observed and, in some axonal terminals, parts of the plas-
mamembrane and the synaptic vesicles membrane have disappeared,
accompanied by the appearance of degenerating membranous struc-
tures [75]. Later, when clinical signs are evident at 56 weeks, lipid
analysis of spinal cord reveals accumulation of PUFA-esteriﬁed-GPL.
The authors proposed that deﬁcient turnover of PUFA-esteriﬁed GPL
of bothmitochondria and axon terminalmembranes triggered sequel-
ae that led to spheroid formation [75].
The null mice described above are devoid of iPLA2β protein
[53,73,75]. More recently, ethylnitrosourea-induced mutagenesis
has been used to generate mice with a point mutation, G373R, in
the 8th ankyrin repeat. In these mice, PLA2β protein is expressed at
wild-type levels but is catalytically-inactive and INAD-like clinical
signs are detected relatively early, at 7–8 weeks of age. Since the
mere absence of iPLA2β catalytic activity results in a much later
onset of clinical signs, the authors suggested that the mutant protein
may exert toxic effects via a dominant-negative role, possibly related
to its protein-binding functions [76].
Early appearing membrane abnormality in synaptic terminals of
iPLA2β-null mice appears consistent with the normal presence in this
location both of the enzyme [54] and of high levels of PUFA-esteriﬁed
GPL (Table 1). It is less obvious why mitochondria are damaged in
thesemice. The related phospholipase, iPLA2γ, has an N-terminal mito-
chondrial localization signal [1]. Disease-associated mutations in the
human gene for iPLA2γ have not been reported, but genetic ablation
of this enzyme in mice causes mitochondrial abnormalities throughout
the brain [77]. Interestingly, in iPLA2β-null mice, brain levels of iPLA2γ
mRNA are reduced by ~40% [65].
Hereditary spastic paraplegias (HSP) comprise a genetically heter-
ogenous group of neurological disorders [78] characterized by degener-
ation of distal parts of long spinal axons [79]. Investigation of members
of two familieswith a rare autosomal-recessive formofHSP (SPG39) re-
vealed mutations in the NTE gene on chromosome 19p13 [80]. Affected
family members had a childhood onset (4–7 years old) of slowly pro-
gressive paraplegia that, in adolescence, worsened to involve progres-
sive atrophy of muscles in the hands and lower distal extremities;
EMG and nerve conduction data indicated progressive motor nerve im-
pairment, but peripheral sensory nerve function was normal, while
magnetic resonance imaging in adulthood revealed atrophy of the tho-
racic spinal cord but no abnormalities in the brain [81].
All three of the mutations in SPG39-HSP are within the catalytic
domain of NTE; in one case a homozygous M1012V mutation and in
the other case a compound heterozygous mutant with R890H on one
allele and, on the other allele, a frame-shift following S982 that causes
a novel sequence of 37 residues followed by a stop-codon [80]. The im-
pact on NTE enzyme activity has been examined by assaying homoge-
nates of cultured skin ﬁbroblasts from affected and non-affected
family members [82]. Both the homozygous and the compound het-
erozygous mutations caused a loss of 35–40% of NTE-esterase activity
as measured with the artiﬁcial substrate, phenyl-valerate. Curiously,
in ﬁbroblasts from non-affected family members with the single het-
erozygous frame-shift mutation, NTE-esterase activity was reduced
by 55–60%, roughly as would be predicted from loss of activity from
one allele. From this the authors speculated that non-catalytic func-
tions of NTE, such as binding to PKA-C3 homologues (see above) or
protein misfolding and consequent ER stress might be the cause of ax-
onal degeneration in HSP-SPG39 [82]. However, mutations in the cat-
alytic domain are unlikely to affect the function of the putative PKA-C3
binding site at the N-terminus of NTE; moreover, pathogenic protein
misfolding as a result of mutation is more likely to show a dominant
pattern of inheritance. It would be informative to repeat the assays
on patient ﬁbroblasts but to use metabolic labeling of intact cells
with [14C]choline and conversion to [14C]GroPCho as a more physio-
logical index of NTE activity.Degenerating and swollen distal axons in the spinal cord are ob-
served in 3-week old NTE-cKO mice and, with age, these lesions in-
crease in number and area affected; clinical signs of sensorimotor
deﬁcit become apparent at ~4 months and worsen thereafter [67].
The distribution of spinal axon lesions and the slowly progressive clin-
ical signs in these mice are highly reminiscent of HSP. Increasing evi-
dence suggests that defects in membrane trafﬁcking and/or axonal
transport are important factors in the pathogenesis of HSP [83]. The
close association between PtdCho homeostasis and membrane traf-
ﬁcking by the constitutive secretory pathway has been noted above
and suggests that NTE-deﬁciency could impair this pathway. Indeed,
measurement of the rates of efﬂux from isolated neurons into culture
medium of proteins that are secreted via the constitutive pathway re-
vealed a moderate reduction (~20%) in neurons from NTE-cKO mice
[67]. This degree of reduction in the secretory pathway does not
cause neuronal death, but might well be expected to have adverse ef-
fects on distal parts of long axons that may require optimal and
uninterrupted function of vesicular trafﬁcking for supplies of mate-
rials from the neuronal soma. This mechanism would be consistent
with the observations that, in NTE-deﬁciency, distal regions of the lon-
gest axons in the nervous system are the ﬁrst to showdamage and that
clinical signs of HSP-SPG39 appear during childhood, but not until
adulthood in NTE-cKO mice with spinal axons that are more than an
order of magnitude shorter than the corresponding human axons
[67]. It is also consistent with earlier experiments which NTE activity
in animals of different sizes was inhibited by dosing with neuropathic
organophosphates: in chickens and cats, a single dosewas sufﬁcient to
induce signs of distal axonal degenerationwithin 2 weeks [56] where-
as, inmice, chronic daily dosing overmanymonthswas required to in-
duce clinical signs of neuropathy [84].
Thus, maintenance of long spinal axons in large adult vertebrates
needs an essentially uninterrupted supply of materials from the neu-
ron at an optimum rate of transport and the latter requires the contin-
uous phospholipase-B activity of NTE. It is paradoxical that peripheral
nerve axons are spared in genetic NTE-deﬁciency, but degenerate in
OP-induced neuropathy. However, as noted earlier, chemical inhibi-
tion of iPLA2β may account for peripheral nerve degeneration in
OP-induced neuropathy. Thus, in peripheral nerve axons, localized
activity of iPLA2β or a related phospholipase, may be sufﬁcient to
maintain PtdCho homeostasis in the absence of NTE. In this regard
it is interesting that peripheral nerve is enriched in a poorly-
characterized enzyme activity previously described as “soluble NTE
activity” [85].
The ﬁrst report of neuropathological change in nestin-cre:NTEﬂ/ﬂ
(i.e., NTE-cKO) mice described spongiform vacuolation of the neu-
ropil, particularly in the hippocampus [62]. Like the spinal axon
lesions, the hippocampal pathology is also progressive from not
detectable at 1 month to readily evident at 3 months to ﬂorid at
12 months (Fig. 2). Loss of pyramidal neurons is a relatively late
event compared to the neuropil vacuolation (Fig. 2). The appearance
of vacuolated neuropil in hippocampal sections from prion-infected
mice has been shown to be an artifact incurred during preparation
of parafﬁn-embedded tissue, probably caused by treatment with sol-
vents that dissolve the contents of pathologically-generated abnor-
mal cellular structures [86]. Since the brain sections from NTE-cKO
mice were also processed in this manner the vacuolation shown in
Fig. 2 arises in the same way. To obtain an alternative view of the un-
derlying pathology, electron-micrographs (EM) were made from
Epon-embedded brain samples. Interpretation of EMs from the hip-
pocampal sections is more complex than from the transverse sections
of spinal cord. Nevertheless, in some sections, membrane-bounded
structures ﬁlled with amorphous-material surrounding a crescent-
shaped cleft are observed (Fig. 2E) and resemble EM-proﬁles of
swollen axons in the spinal cord and brain stem of NTE-cKO mice
[67]. This suggests that, in NTE-cKO mice, hippocampal axons may
degenerate and swell in similar fashion to long spinal axons. Although
Fig. 2. Progressive neuropathological change in hippocampus of NTE-cKO mice. Hematoxylin–eosin stained parafﬁn sections showing CA1-hippocampal region in 12 month
wild-type mouse (A) and NTE-cKO mice at 1 month (B), 3 months (C) and 12 months (D). (E) Electron-micrograph of the same region of hippocampal neuropil from a
12 month NTE-cKO mouse with a putative swollen axon with characteristic cleft in the center of the ﬁeld. (DJ Read and P Glynn, unpublished).
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in the spinal cord, each one has to maintain 20,000–30,000 presynap-
tic terminals, or boutons, with associated synaptic vesicles and exocy-
totic machinery [87]: this entails large amounts of phospholipid
turnover and places considerable metabolic burden on the CA3 hip-
pocampal neurons responsible for their maintenance.
The absence of abnormal magnetic resonance imaging signals in the
brain and of cognitive defects in patients with HSP-SPG39 [80] suggests
that hippocampal pathology is not a feature of this human form of
NTE-deﬁciency. Perhaps this reﬂects the partial loss of NTE activity in
HSP-SPG39 compared to the essentially total ablation fromneural tissue
of NTE-cKOmice. On the other hand, vacuolar pathology was one of the
deﬁning features of the NTE-deﬁcient Drosophila mutant, Swiss cheese
[88]. Cell-selective genetic rescue experiments in these mutant ﬂies in-
dicate that while the vacuolar pathology results from the absence of
NTE activity in neurons, abnormal excessive membrane formation by
glial cells is an autonomous consequence of NTE-deﬁciency in this cell
type [68].Whether, selective deletion of NTE fromvertebrate glia causes
a cell-type-speciﬁc phenotype remains to be determined.4. Concluding remarks
The existence of two recessively-inherited neurological diseases,
INAD/NBIA and HSP/SPG39, indicates that iPLA2β and NTE have
non-redundant functions in neuronal phospholipid deacylation. In
particular, it is clear that the different modes of phospholipid de-
acylation mediated by these two enzymes are both required for struc-
tural integrity of axons and their terminals. Although more details are
required, the evidence reviewed above is beginning to form a picture
of the individual roles of these two phospholipases. iPLA2β liberates
free fatty acid and lysophospholipids from sn-2 hydrolysis of phos-
pholipids. It is tonically-inhibited by Ca2+-calmodulin and this is al-
leviated by autoacylation with oleoyl-coA. iPLA2β is particularly
important for turnover of PUFA-associated phospholipids which, in
the nervous system, are abundant at synaptic terminals. The interplay
between iPLA2β and iPLA2γ in the deacylation of neuronal mitochon-
drial phospholipids remains to be determined. NTE operates primari-
ly at the cytoplasmic face of neuronal ER, but can also be detected in
axons. Its substrate may be nascent PtdCho delivered from the Golgi
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PtdCho may be the major determinant of NTE activity, but PKA-
mediated inhibition may also coordinate its activity with the PtdCho
synthetic pathway. The phospholipase-B activity of NTE degrades
PtdCho to glycerophosphocholine plus two free fatty acids. By this ac-
tivity, NTE reduces PtdCho levels to facilitate the constitutive secreto-
ry pathway and so optimize export of materials from the neuronal
soma. The association between NTE activity and PtdCho synthesis
operates not only in the neuronal soma, but also in the distal axon.
Local PtdCho homeostasis is probably essential for efﬁcient vesicular
transport within the axon, but details of the process are very limited.
An intriguing observation relating to axonal PtdCho homeostasis is
that in genetic NTE-deﬁciency the centrally-projecting long spinal
axon of dorsal root ganglion neurons undergoes distal degeneration
while the peripherally-projecting axon of the same neurons appears
to be spared. It is possible that this is because local iPLA2β activity
compensates for NTE-deﬁciency. Whether agonists acting at neuronal
receptors can modulate the activity of either of these phospholipases
remains an important unaddressed question. Finally, in Section 2 of
this review, attention was called to the need for more precise spatial
resolution of changes in individual GPL species. The study by Beck et
al. (2011) [75], in which IMS was used to visualize differences
between wild-type and iPLA2β mice in individual GPL species with-
in very discrete areas of spinal cord sections, points to the direction
of future investigations. A longer term goal for imaging methods
would be to achieve equivalent spatial resolution (i.e., at the level of
subcellular compartments) for detection of individual GPL species as
is presently possible for proteins by immunohistochemistry.Acknowledgements
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